Data gathered: November 24
AI Stock Analysis - vTv Therapeutics (VTVT)
Analysis generated March 9, 2024. Powered by Chat GPT.
vTv Therapeutics is a biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease, diabetes, and inflammatory disorders. Due to the high-risk nature of drug development in the biotech industry, investments in companies like vTv Therapeutics are usually considered speculative and are subject to high volatility based on trial outcomes and regulatory milestones.
Stock Alerts - vTv Therapeutics (VTVT)
 |
vTv Therapeutics | November 20 Price is down by -5.9% in the last 24h. |
|
vTv Therapeutics | November 19 Price is down by -5.7% in the last 24h. |
|
vTv Therapeutics | November 15 Price is up by 5.5% in the last 24h. |
|
vTv Therapeutics | November 14 Price is up by 5.2% in the last 24h. |
Alternative Data for vTv Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 1,000 | Sign up | Sign up | Sign up |
| Employee Rating | 84 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | 46 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 69 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 14,962 | Sign up | Sign up | Sign up |
| Twitter Followers | 353 | Sign up | Sign up | Sign up |
| Twitter Mentions | 23 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 16 | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | N/A | Sign up | Sign up | Sign up |
About vTv Therapeutics
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs.
| Price | $14.18 |
| Target Price | Sign up |
| Volume | 6,910 |
| Market Cap | $37M |
| Year Range | $12.93 - $29.01 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Drug Manufacturers |
In the news
 |
vTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71%November 16 - Yahoo |
 |
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate UpdateNovember 12 - Yahoo |
 |
vTv Therapeutics Faces License Agreement TerminationOctober 26 - Yahoo |
 |
vTv Therapeutics (NASDAQ:VTVT) Share Price Crosses Below 50 Day Moving Average – Should You Sell?October 4 - ETF Daily News |
Diabetes Pipeline Landscape Research Report 2024: Comprehensive Insights About 200+ Companies and 200+ Pipeline DrugsNovember 21 - GlobeNewswire |
|
 |
VTv Therapeutics: Q3 Earnings SnapshotNovember 12 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 3.3M | -3.3M | -4.8M | 0 | 0.000 |
| Q2 '24 | 0 | 3.7M | -3.7M | -5.2M | -7.1M | -0.809 |
| Q1 '24 | 1M | 4M | -3M | -4.9M | -5.6M | -1.175 |
| Q4 '23 | -9,000 | 2.6M | -2.6M | -3.5M | -4.7M | -1.670 |
| Q3 '23 | 0 | 2.5M | -2.5M | -6.7M | -6.7M | -3.200 |
Insider Transactions View All
| FRY JOHN A filed to buy 61,000 shares at $0.8. November 30 '22 |
| FRY JOHN A filed to buy 20,539 shares at $0.8. November 30 '22 |
| PERELMAN RONALD O filed to sell 36,519,212 shares at $1.2. December 21 '21 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$155.17 0% | 51 |
 |
Eli Lilly and CompanyLLY |
$748.01 0% | 64 |
 |
PfizerPFE |
$25.65 0% | 47 |
 |
AstrazenecaAZN |
$65.63 0% | 71 |
 |
AbbVieABBV |
$176.95 0% | 59 |
Read more about vTv Therapeutics (VTVT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of vTv Therapeutics?
The Market Cap of vTv Therapeutics is $37M.
What is the current stock price of vTv Therapeutics?
Currently, the price of one share of vTv Therapeutics stock is $14.18.
How can I analyze the VTVT stock price chart for investment decisions?
The VTVT stock price chart above provides a comprehensive visual representation of vTv Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling vTv Therapeutics shares. Our platform offers an up-to-date VTVT stock price chart, along with technical data analysis and alternative data insights.
Does VTVT offer dividends to its shareholders?
As of our latest update, vTv Therapeutics (VTVT) does not offer dividends to its shareholders. Investors interested in vTv Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of vTv Therapeutics?
Some of the similar stocks of vTv Therapeutics are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.